FDA Greenlights Three New Drugs as Pharma's Deal Machine Roars
The FDA cleared three therapies this week: Genentech's Gazyva for kidney disease, Alexion's Klygefa for myasthenia gravis and Teva's Igalmi for psychiatric agitation. Johnson & Johnson, Eli Lilly, AmyriAD and Sanofi all signed deals, while Ossium Health pitched bone marrow transplants built on deceased donors.
- Original source: pharmexec.com.
- The source published it on Nov 16, 2026 at 12:07 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA stamped three new therapies this week. Genentech's Gazyva (obinutuzumab) becomes the first and only treatment for primary membranous nephropathy, posting a 36.1% complete proteinuria remission rate at 104 weeks in the Phase III MAJESTY trial, against 5.7% for tacrolimus. Alexion's Klygefa (gefurulimab) landed as a once-weekly, self-administered C5 inhibitor for generalized myasthenia gravis. Teva's Igalmi (dexmedetomidine) sublingual film is the first at-home option for agitation in schizophrenia-spectrum and bipolar disorders.
The dealmaking ran just as hot. Johnson & Johnson agreed to buy Ollin Biosciences for $2.2 billion upfront, with up to $1.125 billion more in milestones — an ophthalmology play partly bankrolled by a $750 million commitment from Blackstone Life Sciences. Eli Lilly, separately, is acquiring Calytrix Bio for up to $1.5 billion to grab a biparatopic antibody aimed at calreticulin-driven blood cancers.
Two more moves rounded out the week. AmyriAD Therapeutics picked up ADvantage Therapeutics' AD04 Alzheimer's program, and Sanofi signed a collaboration with Seawolf Therapeutics worth up to $1.2 billion in bleeding disorder research.
On The Ron Lanton Report, Kevin Caldwell, chief executive officer and co-founder of Ossium Health, laid out a different transplant pipeline — one built on banked marrow from deceased donors instead of living ones. Caldwell says the approach can pull wait times down from a standard of care of 12 to 15 weeks to as little as 31 hours, while keeping more than 90% of cells intact after cryopreservation. Ossium is now working to scale from roughly three donors processed per day toward more than 100 globally.
TopicsGenentech · Alexion · Teva · Johnson & Johnson · Eli Lilly · Sanofi · Ossium Health · Kevin Caldwell
Source: pharmexec.com
Written by AI from verified reporting.

